56 research outputs found
Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study
Pharmacokinetic (PK) studies on recombinant FIX concentrate, Nonacog alpha, were conducted with different sampling time designs which gave rise to not complete and homogenous outcomes. In addition, patient's FIX genotype/PK relationship has never been investigated
Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22
Geometric Configuration of the Anatomical Theater of Padua
This contribution deals with a study carried out on the Anatomical Theater of Padua (built in 1595). Historical documentation research and digital survey advantage the understanding not only the design idea but also its geometric rules of the configuration, through a schematic elaboration based on the digital model
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations
No abstract availabl
Geometric Configuration of the Anatomical Theater of Padua
This contribution deals with a study carried out on the Anatomical Theater of Padua (built in 1595). Historical documentation research and digital survey advantage the understanding not only the design idea but also its geometric rules of the configuration, through a schematic elaboration based on the digital model
Unexpected low prevalence of FVIII gene inversion in severe hemophilia A patients from north-eastern Italy
Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22
"Molecular genotyping of the italian cohort of patients with hemophilia B."
BACKGROUND AND OBJECTIVES: The aim of the study, funded by the Italian Ministry of Health, was to identify the causative mutation in all known patients with hemophilia B in Italy.
DESIGN AND METHODS: Overall, 269 patients followed by 25 regional centers were considered in the study; after exclusion of the related individuals, 238 unrelated patients were analyzed (153 with severe, 59 with moderate and 26 with mild hemophilia B). Screening of the factor IX gene was performed using conformation sensitive gel electrophoresis (CSGE) followed by denaturing high performance liquid chromatography (dHPLC) or direct sequencing in negative cases, or by dHPLC/sequencing (36 cases).
RESULTS: A mutation was identified in 236 of the 238 patients: 6 had large gene deletions (4 total and 2 partial), 14 small deletions, 1 combined deletion/insertion and 215 single nucleotide substitutions. A correlation was observed between the type of mutation and severity of hemophilia; however, a number of patients with the same genotype had varying severities of the disease. Eight of the 169 patients with severe hemophilia B (4.7%) developed inhibitors: 2 of these had a complete gene deletion, 1 had a large partial deletion (from exon A to part of exon H) while 5 had 3 different nonsense mutations. One patient with a nonsense mutation developed anaphylaxis. We also studied 65 families with hemophilia B involving 144 females (14 obligatory carriers, 85 carriers and 45 non-carriers) and performed 12 antenatal diagnoses.
INTERPRETATION AND CONCLUSIONS: The data have been used to build the Italian mutation database to provide each family with knowledge of the disease-causing defect for genetic counseling. This Italian study confirms the marked heterogeneity of factor IX mutations in the population and the presence of a degree of genotype/phenotype discordance. The identification of the mutation can also be used to predict risk of inhibitor development
Hepatitis C virus quasispecies in the natural course of HCV-related disease in patietns with haemophilia
Patients with haemophilia show high prevalence of hepatitis C infection but low rate of progressive liver disease when they are not co-infected with HIV. The balance between host immune system and hepatitis C virus (HCV) variability seems to play a major role in the evolution of the HCV-related disease. To address this point we have studied, in a group of selected patients with haemophilia, the composition and in some cases the evolution, of the highest variable envelope gene within the hypervariable region 1 (HVR1) of the HCV, which is the region more directly exposed to the host immune response. Five of 12 patients show a very high homogeneity of the HVR1 and four of those had severe progressive liver disease. These results seem to confirm the major role of the immunity in driving the variability of the HCV rather than the high degree of different HCV strains to which haemophiliacs have been in touch with, during their long-term replacement therapy. Our results seem in keeping with other studies on different type of patients, where a low degree of quasispecies variability has been demonstrated in relationship with the progression and the severity of their liver disease
- …